Pozelimab,a new generation of C5 complement inhibitors for CHAPLE disease

VernacularTitle:治疗CHAPLE病的新一代C5补体抑制药帕泽利单抗
Author: Xuan-Ling ZHANG ¹ ; Chao-Yang CHEN ; Ran WEI ; Ying ZHOU
Author Information

1. 北京大学第一医院药学部,北京 100034
Keywords: Pozelimab; complement factor H-related protein 5 deficiency type protein-losing enteropathy
From: The Chinese Journal of Clinical Pharmacology 2024;40(2):276-278
CountryChina
Language:Chinese
Abstract: On August 18,2023,the U.S.Food and Drug Administration(FDA)officially approved Regeneron's Pozelimab-bbfg(Veopoz?)for the treatment of complement factor H-related protein 5 deficiency type protein-losing enteropathy(CHAPLE)disease in children aged 1 and above,as well as adult patients.CHAPLE disease is a rare condition.Pazelimab monoclonal antibody is a recombinant monoclonal antibody(immunoglobulin G4 isotype).This antibody works by binding to the terminal complement protein C5,thereby preventing the cleavage of C5 into C5a(an anaphylatoxin)and C5b,and inhibit the activation of the terminal complement pathway.This article provides an overview of Pozelimab-bbfg,including its pharmacological research,pharmacokinetics,clinical studies,safety profile,and more,to introduce the current state of research and the achievements made with this drug.